Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing targeted therapeutics for eczema, dermatological and chronic wound disorders, psoriasis, and
acne. It intends to use the BioLexa Platform to develop 2 topical cream products that treat eczema and reduces post-procedure infections for patients undergoing aesthetic dermatology procedures. The company has a sponsored research agreement with the George Washington University to counter the dermatological related side-effects of Erlotinib therapy in cancer patients; and research collaboration agreement with Weill Cornell Medicine to examine the ability of retinoic acid metabolism blocking agents (RAMBA) to block acne pathogenic gene expression in human keratinocytes, mouse skin, and carcinogenesis in mice. The company was incorporated in 2017 and is headquartered in New York, New York. The company trades on NASDAQ exchange. The company headquarter is located in New York, NY. The company was established in the 2017.
| Ticker | HOTH |
| Long Name | Hoth Therapeutics, Inc. |
| Short Name | Hoth Therapeutics |